Teva Pharmaceutical Industries Limited and Antares Pharma, Inc. received a Supplemental New Drug Application (sNDA) approval, which added “needle-free injection” to its Tev-Tropin [somatropin (rDNA) for injection] brand human growth hormone (hGH) drug label. Antares needle-free device will be marketed by Teva under the name-the Tev-Tropin Tjet Injector system.

“We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares, and to offer patients a less invasive delivery system,” stated Larry Downey, head of Teva’s North America Brand Pharmaceuticals division. “This significant achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to utilize our global strengths in innovative activities.”

“This is the first product approval stemming from our portfolio of product collaborations with Teva and is a very exciting milestone for the Company” said Paul K. Wotton, President and Chief Executive Officer of Antares Pharma. “Importantly it is another example of delivering on our strong focus and commitment to patients, together with our partners, to provide new ways to administer drugs. We look forward to the launch of this product by Teva.”

Antares currently markets its needle-free injection system through its partners in Europe, Japan and Asia.